Marit Eika Jørgensen

Suggest Changes

Writes About:

Learn More
BACKGROUND In patients with type 2 diabetes and a high cardiovascular risk profile, the sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower(More)
The U.S. Food and Drug Administration warns that sodium–glucose cotransporter 2 (SGLT2) inhibitors may lead to diabetic ketoacidosis (DKA). To establish a baseline occurrence of DKA in type 2(More)